We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Melanie
Pattrick
m.pattrick@nhs.net
Dr
William
Alazawi
w.alazawi@qmul.ac.uk
Dr
William
Alazawi
w.alazawi@qmul.ac.uk
Diseases of liverDiabetes mellitus
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Deaths from liver disease are rising more rapidly than any other cause of death in the UK. The most common cause of chronic liver injury in the developed world is non-alcoholic fatty liver disease (NAFLD), which is found in up to 75% of patients with diabetes. NAFLD is a spectrum of diseases that includes simple fat deposition to the more aggressive form involving inflammation and scarring in the liver (non-alcoholic steatohepatitis (NASH)) that can progress to cirrhosis, liver failure and liver cancer.
The factors that determine whether an individual patient will develop the more aggressive NASH are not fully understood although a combination of genetic, environmental and lifestyle factors are likely to play a role. There has been recent interest in the effect of ethnicity in the progression of NAFLD and our group has recently reported that NAFLD is three times more common among patients of Bangladeshi origin compared to other ethnic groups – including other South Asian groups.
Our aim is to study the degree to which NAFLD and NASH affect patients with diabetes from different ethnicities and to develop guidelines to help doctors manage patients with NAFLD in an ethnically diverse population, such as ours.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cross-sectional;
You can take part if:
You may not be able to take part if:
• Any inclusion criteria not met • under 18 years • with type 1 DM • existing diagnosis of non-NAFLD chronic liver disease • taking medication associated with liver dysfunction • unable to consent
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
William
Alazawi
w.alazawi@qmul.ac.uk
Melanie
Pattrick
m.pattrick@nhs.net
Dr
William
Alazawi
w.alazawi@qmul.ac.uk
The study is sponsored by Queen Mary University of London and funded by DIABETES RESEARCH & WELLNESS FOUNDATION .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 17569
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
